Browse the evidence

Discontinuation of anti-obesity medications (AOMs) leads to significant weight regain starting at 8 weeks post-treatment, with the trajectory stabilizing by 26 weeks.

If you stop taking anti-obesity medication, expect to regain weight starting around 2 months later. This is a biological response to the loss of the drug's appetite-suppressing effects, not a lack of willpower. Long-term management likely requires ongoing treatment or intensive lifestyle support to counteract this regain.

Adherence to the Mediterranean diet (MeDi) is associated with improved cognitive performance and a delay in cognitive decline in elderly populations, particularly when enriched with extra virgin olive oil or nuts.

Adopt a Mediterranean-style eating pattern focusing on extra virgin olive oil, vegetables, fruits, whole grains, and nuts. This approach is more effective for cognitive health than taking single supplements. Prioritize high-polyphenol olive oil and moderate wine intake if appropriate for your health profile.

Plant-based diets, particularly those emphasizing nutritious plant foods, are associated with a reduced risk of cognitive impairment and dementia compared to non-vegetarian diets.

Shift your diet to center around plants: vegetables, fruits, whole grains, legumes, nuts, and seeds. This pattern is linked to a significantly lower risk of dementia. Ensure you are eating 'nutritious' plant foods, as less healthy plant-based patterns may not offer the same benefits.

GLP-1 analogs and SGLT-2 inhibitors are promising therapeutic modalities for the obese-diabetic phenotype of HFpEF, with GLP-1 analogs showing significant reduction in epicardial adipose tissue (EAT) and body weight.

Newer diabetes drugs (GLP-1s and SGLT-2 inhibitors) are highly effective for obese HFpEF patients. They help lose weight, reduce heart fat (EAT), and improve heart function. GLP-1s like semaglutide can lead to substantial weight loss (up to 10% or more).

Triple agonists (GLP-1/GIP/Glucagon) like retatrutide achieve even greater weight loss (>24%) than dual agonists, likely due to the addition of glucagon receptor agonism which increases energy expenditure.

Triple-agonist injections like retatrutide (12 mg/week) are showing even higher weight loss rates (~24%) than current dual agonists in early trials. This is due to the addition of glucagon stimulation, which boosts energy expenditure. These are still in development and not yet widely approved for obesity.

Low intake of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) significantly amplifies the cardiovascular disease (CVD) risk associated with having a family history of CVD, whereas low intake of other polyunsaturated fatty acids (linoleic acid and alpha-linolenic acid) does not show this interaction.

If you have a family history of heart disease, your risk is significantly higher if your levels of EPA and DHA (found in oily fish) are low. While general healthy fats are good, ensuring adequate intake of EPA/DHA is specifically critical for you to mitigate this genetic risk. Aim to consume oily fish regularly to raise these biomarkers.

Physical activity alone is an effective strategy for reducing obesity and related comorbidities, particularly abdominal fat, even without dietary energy restriction.

To lose fat, you do not necessarily need to diet. Engaging in 45-60 minutes of moderate exercise daily is sufficient to reduce body mass and abdominal fat. Focus on consistency rather than extreme intensity if you are not restricting calories.

Exercise interventions typically result in less weight loss than predicted by simple energy balance models due to metabolic and behavioral compensation.

Do not be discouraged if you do not lose weight as fast as you calculate. Your body will try to compensate by making you hungrier or moving less. Focus on the health benefits and consistency rather than just the scale.

Bariatric surgery significantly reduces the incidence of new-onset type 2 diabetes, hypertension, and dyslipidemia in severely obese individuals compared to no intervention.

For severely obese individuals, bariatric surgery is a highly effective preventive measure against developing type 2 diabetes, high blood pressure, and high cholesterol. The study shows that surgery reduces the risk of developing these conditions by 55-94% compared to no treatment. This should be a key factor in treatment decisions for severe obesity, especially in regions with high metabolic disease rates.

Bariatric surgery yields significantly higher rates of complete and prolonged diabetes remission compared to usual care (lifestyle and medication management).

For patients with Type 2 Diabetes, bariatric surgery is a more effective intervention for achieving remission than lifestyle changes and medications alone. While surgery carries risks and potential for relapse, the data shows it significantly outperforms standard care in both complete and prolonged remission rates. Patients should discuss their eligibility and specific surgical options (like RYGB or Sleeve Gastrectomy) with their healthcare provider, weighing the higher remission probability against surgical risks.

Bariatric surgery patients often have higher baseline HbA1c and require more insulin, yet still achieve higher remission rates than usual care patients.

Even if your diabetes is severe (high HbA1c) or you require insulin, bariatric surgery may still offer a chance for remission, potentially more so than lifestyle changes alone. Do not rule out surgery solely based on the severity of your diabetes or current medication use.

GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) and slow chronic kidney disease progression in Type 2 Diabetes, but evidence for improving heart failure outcomes is mixed or insufficient.

If you have Type 2 Diabetes and high heart risk or kidney issues, GLP-1 agonists (like Ozempic, Trulicity, or Victoza) are highly recommended to prevent heart attacks and protect kidneys. However, they are not currently proven to treat existing heart failure. If you struggle with injections, ask about oral semaglutide.

Physical activity attenuates the obesity-increasing genetic effects associated with the FTO locus by approximately 20-30%.

If you have a family history of obesity linked to the FTO gene, regular physical activity is not just beneficial—it is a critical counter-measure. Engaging in regular exercise can reduce the genetic impact on your BMI by 20-30%, proving that lifestyle choices actively modify genetic risk.

FTO gene variants interact with sweet beverage consumption and alcohol intake to influence obesity and blood pressure.

If you have the FTO gene variant, be particularly mindful of your intake of sweet beverages and alcohol, as these interact with your genetics to increase obesity and blood pressure risk.

Lifestyle-mediated weight loss interventions (diet and/or exercise) induce significant DNA methylation changes in blood leukocytes and adipose tissue, potentially serving as biomarkers for predicting individual response to therapy and reflecting systemic metabolic improvements.

Lifestyle changes like diet and exercise don't just change your weight; they change how your genes are expressed. This means your body's biological response to weight loss is unique and can potentially be predicted by looking at specific DNA markers before you start. Consistent lifestyle interventions can reverse obesity-associated epigenetic patterns.

Baseline DNA methylation levels can serve as prognostic biomarkers to predict which individuals will successfully lose weight in response to lifestyle interventions.

Your body's current epigenetic state might tell you how well you'll respond to a specific diet or exercise plan before you even start. This suggests a future where weight loss strategies are tailored based on your unique biological markers rather than just your current weight.

GLP-1 receptor agonists reduce the risk of heart failure hospitalization, with the most significant relative risk reduction observed in patients with heart failure with preserved ejection fraction (HFpEF) who have obesity.

If you have heart failure with preserved ejection fraction (HFpEF) and are overweight or obese, GLP-1 medications like semaglutide or efpeglenatide may significantly reduce your risk of being hospitalized for heart failure. These drugs work by improving blood sugar, reducing weight, and lowering inflammation. While not yet a standard treatment for all heart failure, they are a promising option, especially for those with obesity.

Bile acids, particularly lithocholic acid and hyocholic acid, improve glucose tolerance by activating the GPCR GPBAR1 (TGR5) on enteroendocrine cells, leading to increased GLP-1 secretion and insulin release.

Bile acids play a crucial role in glucose regulation by activating the GPBAR1 receptor, which stimulates the release of GLP-1 and insulin. This effect is particularly pronounced after meals containing fats and cholesterol, as bile acid levels rise. Post-bariatric surgery patients often experience improved glucose tolerance due to increased circulating bile acids. Maintaining a healthy gut microbiome may also influence bile acid composition and effectiveness.

Unsaturated fatty acids, particularly omega-3 PUFAs like linoleic, oleic, and docosahexaenoic acid, stimulate insulin and glucagon secretion via activation of FFAR1 and FFAR4, improving glucose tolerance.

Incorporate unsaturated fatty acids, especially omega-3 PUFAs found in fish, nuts, and seeds, into your diet. These fatty acids activate FFAR1 and FFAR4 receptors, which can stimulate the release of insulin and glucagon, helping to regulate blood sugar levels. This is particularly beneficial for individuals with insulin resistance or type 2 diabetes.

Semaglutide improves NASH resolution in patients with stage 1-3 fibrosis but does not improve fibrosis or NASH resolution in patients with NASH-related cirrhosis.

Semaglutide can help resolve NASH in patients with early to moderate fibrosis, but it is not effective for reversing scarring in advanced cirrhosis, even if it helps with weight and metabolic markers.

Semaglutide achieves the highest response rate for NASH resolution without worsening fibrosis in clinical trials, but does not reverse fibrosis despite significant weight loss.

Semaglutide is currently the most effective drug for resolving NASH without worsening fibrosis, but it does not reverse existing fibrosis. It should be considered for patients who do not achieve goals with lifestyle changes alone, under medical supervision.

Quitting smoking after a new diagnosis of type 2 diabetes reduces the risk of cardiovascular disease and mortality, although the risk remains higher than in those who never smoked.

If you smoke, quit. Even after a diabetes diagnosis, stopping smoking lowers your risk of heart attack and death compared to continuing. While your risk might not drop to the level of someone who never smoked, it is much better than staying a smoker. Combine this with exercise for the best results.

Tirzepatide treatment (5-15 mg once weekly) reduces albuminuria (UACR) without causing adverse changes in estimated glomerular filtration rate (eGFR) in individuals with overweight or obesity, with or without type 2 diabetes.

If you have overweight or obesity, with or without type 2 diabetes, tirzepatide (a weekly injection) has been shown to improve kidney markers (specifically reducing albuminuria) without negatively impacting kidney filtration function. This benefit was observed across different doses (5-15 mg) over 72 weeks, alongside lifestyle changes. This suggests it may be a kidney-protective option for this population, particularly those with existing elevated albuminuria.

Discontinuation of GLP-1 RA therapy is associated with significant weight regain, loss of cardiorenal protection, and an increased risk of Major Adverse Cardiovascular Events (MACE).

If you stop taking your GLP-1 medication (like Ozempic or Wegovy), you are likely to regain much of the weight you lost. More importantly, studies show that stopping these drugs increases your risk of heart attacks, strokes, and other cardiovascular events. If you are considering stopping due to side effects, talk to your doctor about adjusting the dose or switching medications rather than stopping abruptly, to protect your heart and maintain your weight loss.